-5%
Famas is indicated in-Â
- Gastric ulcer
- Duodenal ulcer
- Anastomotic ulcer
- Acute stress ulcer
- Reflux esophagitis and
- Zollinger-Ellison syndrome.
Famas is also indicated for the treatment of acute gastritis and chronic gastritis in the acute exacerbation stage.
Famotidine is a histamine H2-receptor antagonist. Famotidine completely inhibits the action of histamine on H2- receptors of parietal cells. It inhibits basal, overnight, and pentagastrin-stimulated gastric acid secretion. The H2- receptor antagonist activity of Famotidine is slowly reversible, since the drug dissociates slowly from the H2-receptor.
No clinically important drug interactions have been identified. Famas does not interact with the cytochrome P450-linked drug-metabolizing enzyme system.
Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Caution should be exercised when Famotid is administered to a nursing woman.
The drug should be used in the minimum required amount, depending on the conditions of the disease. The drug should be administered carefully in elderly patients, patients with renal failure, and patients with hepatic disorders.